egfr inhibitor造句
例句与造句
- Expression levels of cripto are associated with resistance to EGFR inhibitors.
- New EGFR inhibitors include afatinib and dacomitinib.
- Cetuximab and other EGFR inhibitors only work on tumors in which KRAS is not mutated.
- This allows activation of the downstream effectors of EGFR even in the presence of an EGFR inhibitor.
- Additional studies should confirm and further define its role in predicting EGFR inhibitors benefit . { { Cite journal
- It's difficult to find egfr inhibitor in a sentence. 用egfr inhibitor造句挺难的
- Little is known about the effects of EGFR inhibitors in SC, although some evidence suggests that these tumors are not likely to be highly responsive.
- Studies have indicated that detection of KRAS gene mutations helps physicians identify patients that are unlikely to respond to treatment with targeted EGFR inhibitors, including cetuximab and panitumumab.
- Epidermal growth factor receptor ( EGFR ) is another validated target in NSCLC . Additionally, the T790M gatekeeper mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors.
- The toxicity and safety of nimotuzumab have been assessed in several pre-clinical and clinical studies wherein it was noticed that side effects usually caused by EGFR inhibitors, especially rashes and other skin toxicities, were negligible.
- The most common adverse effect of EGFR inhibitors, found in more than 90 % of patients, is a papulopustular rash that spreads across the face and torso; the rash's presence is correlated with the drug's antitumor effect.
- While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native ( endogenous or unmutated ) EGFR . A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy.
- Accordingly, genetic testing to confirm the absence of KRAS mutations ( and so the presence of the KRAS wild-type gene ), is now clinically routine before the start of treatment with EGFR inhibitors . mCRC patients with wild-type KRAS tumors have been shown to benefit from a response rate of over 60 % and a decreased risk for progression of over 40 % when treated with Erbitux as 1st-line therapy.